Latest news with #SusanFitzpatrick-Napier
Yahoo
20-05-2025
- Business
- Yahoo
TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the 'Outstanding Patient Recruitment and Retention' Category
TrialWire™ is the risk-share pay-per-enrolled AI and algorithm-powered patient recruitment Platform built on Salesforce Health Cloud for industry-leading patient data and IP security CRO Awards SAN FRANCISCO, May 20, 2025 (GLOBE NEWSWIRE) -- TrialWire today announces it was named a Fierce CRO Award finalist by Fierce Biotech in the Outstanding Patient Recruitment and Retention category. TrialWire is the AI and algorithm-powered patient-recruitment and enrollment platform, purpose-built on Salesforce Health Cloud to guarantee best-in-class data and IP security. The Platform is a risk share pay-per-enrolled patient offering that accelerates global studies across multiple languages and cultures as well as single country or regional studies, and hybrid decentralized trials. The Platform is specifically designed to rescue stalled trials with its lead product RapidRescue™. Pre-register your study here just in-case Sponsors and CROs who want recruitment certainty from startup can also leverage TrialWire's curated custom patient registry solution GeoClinical™ to boost enrollment from Site activation. TrialWire starts recruiting in under 24 hours and delivers, with complete HIPAA and GDPR compliance, across even the toughest therapeutic areas and protocols. More than 17,000 studies are now pre-registered on the Platform just in case they need a rapid patient recruitment boost. The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards honor CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-quality research and development services. By recognizing the excellence of CROs, the awards aim to highlight the critical role they play in advancing life sciences research and improving patient outcomes. 'We are honored to be selected as one of only three global finalists in the Fierce Biotech CRO Awards for 'Outstanding Patient Recruitment and Retention',' said Director Susan Fitzpatrick-Napier. 'We are a young technology company designed to help Sponsors and Sites securely recruit and enroll smarter and faster, and to accelerate communications between Sites and patients to maximize retention. With more than 80% of trials delayed, and often fail, due to patient recruitment issues we are proud to be the go-to solution for some of the most challenging trials, especially in oncology, rare diseases, and CNS. Our recruitment team brings 10+ years of hands-on experience across hundreds of protocols and TAs, while our industry-leading Platform developers have uniquely optimized the experience for patients, Sites, Sponsors, and CROs - meeting the highest standards of data security. Thank you to our clients, partners, and the Fierce Biotech judges for this recognition.' The Fierce CRO Awards finalists were judged on: Innovation and Impact, Measurable Outcomes, Sustainability and Scalability and Ethical and Regulatory Adherence. Fierce CRO Awards winners will be announced on June 18. About is the leading digital patient recruitment Platform, purpose-built to address the biopharma challenges of clinical trial enrollment. TrialWire's RapidRescue™ solution combines advanced AI-driven technology, health algorithms, real-time communication tools, and robust data insights. TrialWire rapidly identifies, screens, and connects eligible participants to clinical trials, significantly reducing enrollment timelines and associated costs. The platform is built on Salesforce Health Cloud, ensuring the highest levels of security and compliance. More than 17,000 studies are now pre-registered just in case they need a rapid patient recruitment boost. Pre-register your study here just in-case About Fierce Biotech is the biotech industry's daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free here. Media ContactDavid JamesMedia Advisor DMG AgencyTeam@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-04-2025
- Health
- Yahoo
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of blindness among working-age adults. Without timely intervention, NPDR can progress to more severe stages of diabetic eye disease, increasing the risk of vision loss. This milestone marks a significant step forward in the clinical development of VX-01, potentially the first oral treatment for this condition, designed to target the inflammatory mechanisms underlying NPDR progression. 'We are pleased to initiate patient dosing in this important Phase 2 study, which evaluates VX-01 as a potential early intervention for diabetic retinopathy,' said Alek Safarian, Co-Founder and Chairman of Vantage Biosciences. 'By targeting the disease at an earlier stage, VX-01 has the potential to slow or prevent progression to more severe forms of diabetic retinopathy, reducing the likelihood that patients will require invasive treatments in the future.' The Phase II study is expected to read out in 2027 and is being run at 27 sites across the US, Australia, and a number of Southeast Asian countries. About the VX01-DR-201 Study This is a Phase 2, multi-center, double-masked, randomized, placebo-controlled study designed to evaluate the efficacy of oral dose of VX-01 in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Eligible participants will be randomized 1:1 into one of two study cohorts. All participants will take VX-01 or placebo BID for 52 consecutive weeks, followed by a 12-week post-treatment observation period. About VX-01 VX-01 is an orally administered small molecule therapy designed to target neurovascular inflammation associated with diabetic eye disease. By addressing the underlying biological processes that contribute to microvascular complications in the retina, VX-01 aims to slow or prevent disease progression in NPDR patients before irreversible vision loss occurs. About Vantage Biosciences Vantage Biosciences is a clinical stage biotechnology company dedicated to developing innovative therapies for diabetic eye diseases. Founded by ALSA Ventures, the company is committed to scientific excellence and patient-centred approach in advancing treatments that address significant unmet medical needs in diabetic eye disease. Vantage Biosciences is backed by ALSA Ventures, a leading biotech investment firm focused on the creation and development of breakthrough therapeutic companies. For more information, visit ALSA Ventures. CONTACT: Media contact: DMG Biopharma Agency Susan Fitzpatrick-Napier Team@ in to access your portfolio
